Intravenous administration of anakinra in children with macrophage activation syndrome

BACKGROUND: Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiopathic arthritis. Recent reports suggest anakinra can be a valuable addition to the treatment of COVID-19 associated cytokine storm syndrome and the related multisystem inflammatory syndrome (MIS-C) in childre...

Descripción completa

Detalles Bibliográficos
Autores principales: Phadke, Omkar, Rouster-Stevens, Kelly, Giannopoulos, Helen, Chandrakasan, Shanmuganathan, Prahalad, Sampath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240425/
https://www.ncbi.nlm.nih.gov/pubmed/34187503
http://dx.doi.org/10.1186/s12969-021-00585-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240425/
https://www.ncbi.nlm.nih.gov/pubmed/34187503
http://dx.doi.org/10.1186/s12969-021-00585-3

Ejemplares similares